×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
RGEN – repligen corporation (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
RGEN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/5
08:08 am
rgen
Repligen Corporation to Present at Upcoming March Conferences [Yahoo! Finance]
Low
Report
Repligen Corporation to Present at Upcoming March Conferences [Yahoo! Finance]
3/5
07:30 am
rgen
Repligen Corporation to Present at Upcoming March Conferences
Low
Report
Repligen Corporation to Present at Upcoming March Conferences
3/5
06:01 am
rgen
Repligen (RGEN) was downgraded by Weiss Ratings from "hold (c-)" to "sell (d+)".
Low
Report
Repligen (RGEN) was downgraded by Weiss Ratings from "hold (c-)" to "sell (d+)".
3/3
10:03 am
rgen
3 Reasons to Avoid RGEN and 1 Stock to Buy Instead [Yahoo! Finance]
Low
Report
3 Reasons to Avoid RGEN and 1 Stock to Buy Instead [Yahoo! Finance]
2/25
03:40 pm
rgen
Repligen (RGEN) had its price target lowered by UBS Group AG from $200.00 to $195.00. They now have a "buy" rating on the stock.
Low
Report
Repligen (RGEN) had its price target lowered by UBS Group AG from $200.00 to $195.00. They now have a "buy" rating on the stock.
2/25
11:32 am
rgen
Repligen (RGEN) had its price target lowered by Barclays PLC from $200.00 to $175.00. They now have an "overweight" rating on the stock.
Low
Report
Repligen (RGEN) had its price target lowered by Barclays PLC from $200.00 to $175.00. They now have an "overweight" rating on the stock.
2/25
10:24 am
rgen
Repligen (RGEN) had its price target lowered by Wells Fargo & Company from $190.00 to $180.00. They now have an "overweight" rating on the stock.
Low
Report
Repligen (RGEN) had its price target lowered by Wells Fargo & Company from $190.00 to $180.00. They now have an "overweight" rating on the stock.
2/25
10:07 am
rgen
Repligen (RGEN) had its "overweight" rating reaffirmed by KeyCorp.
Low
Report
Repligen (RGEN) had its "overweight" rating reaffirmed by KeyCorp.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/5
01:29 pm
rgen
Form 4 REPLIGEN CORP For: Mar 04 Filed by: Bylund James
Low
Report
Form 4 REPLIGEN CORP For: Mar 04 Filed by: Bylund James
3/5
01:25 pm
rgen
Form 4 REPLIGEN CORP For: Mar 04 Filed by: KURIYEL RALF
Low
Report
Form 4 REPLIGEN CORP For: Mar 04 Filed by: KURIYEL RALF
3/3
02:02 pm
rgen
Form 4 REPLIGEN CORP For: Feb 27 Filed by: Bylund James
Low
Report
Form 4 REPLIGEN CORP For: Feb 27 Filed by: Bylund James
3/3
01:39 pm
rgen
Form 4 REPLIGEN CORP For: Feb 27 Filed by: Loeillot Olivier
Low
Report
Form 4 REPLIGEN CORP For: Feb 27 Filed by: Loeillot Olivier
3/3
01:38 pm
rgen
Form 4 REPLIGEN CORP For: Mar 02 Filed by: Hunt Anthony
Low
Report
Form 4 REPLIGEN CORP For: Mar 02 Filed by: Hunt Anthony
3/3
01:33 pm
rgen
Form 4 REPLIGEN CORP For: Feb 27 Filed by: Garland Jason K
Low
Report
Form 4 REPLIGEN CORP For: Feb 27 Filed by: Garland Jason K
3/3
01:31 pm
rgen
Form 4 REPLIGEN CORP For: Feb 27 Filed by: KURIYEL RALF
Low
Report
Form 4 REPLIGEN CORP For: Feb 27 Filed by: KURIYEL RALF
3/3
12:48 pm
rgen
Form 4 REPLIGEN CORP For: Mar 02 Filed by: Douglass Brian Robb
Low
Report
Form 4 REPLIGEN CORP For: Mar 02 Filed by: Douglass Brian Robb
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/3
Edwards Lifesciences Shows Improved Price Strength & IBD Rating Upgrade [Investor's Business Daily]
8.7%
7/15 Form 8-K REPLIGEN CORP For: Jul 15 7.9%
10/31 Repligen Exits Third Quarter Armed With a $500 Million War Chest [The Motley Fool] 6.6%
4/22 Repligen to Report First Quarter 2020 Financial Results 5.4%
3/10 Repligen Co. (NASDAQ: RGEN) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. 4.8%
6/4 Repligen to Present at Jefferies 2019 Healthcare Conference 4.8%
4/28 Form DEF 14A REPLIGEN CORP For: May 13 4.6%
11/14 Repligen Co. (NASDAQ: RGEN) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating on the stock. 3.4%
5/9 Q1/2019 3/31/2019 EPS 0.280 ZacksConsensus 0.260 ActVsEst 0.020 - Beat 3.4%
5/15 Form 4 REPLIGEN CORP For: May 13 Filed by: Snodgres Jon 3.3%
7/15 Form 8-K REPLIGEN CORP For: Jul 15 7.9%
10/31 Repligen Exits Third Quarter Armed With a $500 Million War Chest [The Motley Fool] 6.6%
4/22 Repligen to Report First Quarter 2020 Financial Results 5.4%
3/10 Repligen Co. (NASDAQ: RGEN) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. 4.8%
6/4 Repligen to Present at Jefferies 2019 Healthcare Conference 4.8%
4/28 Form DEF 14A REPLIGEN CORP For: May 13 4.6%
11/14 Repligen Co. (NASDAQ: RGEN) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating on the stock. 3.4%
5/9 Q1/2019 3/31/2019 EPS 0.280 ZacksConsensus 0.260 ActVsEst 0.020 - Beat 3.4%
5/15 Form 4 REPLIGEN CORP For: May 13 Filed by: Snodgres Jon 3.3%
TOP News Decliners
3/13
IBD Watchlists See Frothy Tide Of Incoming Stocks Amid Coronavirus Correction [Investor's Business Daily]
-11.7%
3/23 Repligen Co. (NASDAQ: RGEN) had its price target lowered by analysts at HC Wainwright from $110.00 to $100.00. They now have a "buy" rating on the stock. -10.2%
3/18 Form 4 REPLIGEN CORP For: Mar 16 Filed by: RYAN THOMAS F JR -9.8%
2/20 Repligen Reports Fourth Quarter and Full Year 2019 Financial Results -8.1%
2/24 Form 4 REPLIGEN CORP For: Feb 21 Filed by: DAWES KAREN A -7.7%
8/1 Form 10-Q REPLIGEN CORP For: Jun 30 -6.7%
8/2 Repligen Corporation (RGEN) CEO Tony Hunt on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -5.7%
8/1 Q2/2019 6/30/2019 EPS 0.310 ZacksConsensus 0.250 ActVsEst 0.060 - Beat -4.3%
4/6 Form 4 REPLIGEN CORP For: Apr 03 Filed by: BARTHELEMY NICOLAS -3.5%
2/6 Repligen to Report Fourth Quarter and Full Year 2019 Financial Results -3.4%
3/23 Repligen Co. (NASDAQ: RGEN) had its price target lowered by analysts at HC Wainwright from $110.00 to $100.00. They now have a "buy" rating on the stock. -10.2%
3/18 Form 4 REPLIGEN CORP For: Mar 16 Filed by: RYAN THOMAS F JR -9.8%
2/20 Repligen Reports Fourth Quarter and Full Year 2019 Financial Results -8.1%
2/24 Form 4 REPLIGEN CORP For: Feb 21 Filed by: DAWES KAREN A -7.7%
8/1 Form 10-Q REPLIGEN CORP For: Jun 30 -6.7%
8/2 Repligen Corporation (RGEN) CEO Tony Hunt on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -5.7%
8/1 Q2/2019 6/30/2019 EPS 0.310 ZacksConsensus 0.250 ActVsEst 0.060 - Beat -4.3%
4/6 Form 4 REPLIGEN CORP For: Apr 03 Filed by: BARTHELEMY NICOLAS -3.5%
2/6 Repligen to Report Fourth Quarter and Full Year 2019 Financial Results -3.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: